Linoladiol N

Estradiol hemihydrate, the active ingredient in Linoladiol N, is an estrogen presented as a vaginal formulation for local use. It treats estrogen‑deficiency related conditions such as menopausal symptoms and vaginal atrophy in post‑menopausal women, helping to restore normal estrogen‑dependent physiological functions.

GNH USA supplies Linoladiol N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linoladiol N provides estrogen replacement for conditions linked to reduced endogenous estrogen.

- Menopausal symptoms: alleviates hot flashes, night sweats and mood changes associated with menopause. - Vaginal atrophy: improves dryness, itching, irritation and dyspareunia caused by estrogen deficiency. - Estrogen deficiency: restores estrogen‑dependent physiological functions such as bone density maintenance and urogenital health.

Adverse reactions may occur with vaginal estrogen therapy.

Common Side Effects: - Vaginal irritation or burning sensation - Increased vaginal discharge or spotting - Breast tenderness or enlargement - Headache or mild nausea

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Endometrial hyperplasia or carcinoma risk if systemic absorption is significant - Severe allergic reaction (anaphylaxis, angioedema) - Liver function abnormalities - Unexplained vaginal bleeding

Use Linoladiol N only after careful clinical assessment and under medical supervision.

- Contraindications: do not use in women with known estrogen‑dependent neoplasia or active thromboembolic disease. - Monitor: regularly assess for signs of thrombosis, breast changes, or abnormal uterine bleeding. - Breast health: perform periodic clinical breast examinations and imaging as indicated. - Dose: employ the lowest effective dose for the shortest duration needed. - Concomitant therapy: avoid simultaneous use of other estrogen products unless specifically directed. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Estradiol hemihydrate may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Combined estrogen or hormonal therapy: increases risk of thromboembolic events and estrogen‑related adverse effects. - Strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin): may reduce estradiol plasma concentrations. - Tamoxifen or aromatase inhibitors: antagonize estrogenic activity and can diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may modestly affect estradiol metabolism. - Antihypertensive agents: estrogen can potentiate fluid retention, requiring blood pressure monitoring.